초록 ▼

A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type III phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, wherein administ

A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type III phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, wherein administration is transurethral, topical or transdermal. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.

대표청구항 ▼

[ What is claimed is:] [1.] A method for treating erectile dysfunction in a male individual, comprising administering to the individual a therapeutically effective amount of a pharmaceutical formulation comprised of a Type III phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester,

[ What is claimed is:] [1.] A method for treating erectile dysfunction in a male individual, comprising administering to the individual a therapeutically effective amount of a pharmaceutical formulation comprised of a Type III phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or prodrug thereof, wherein the formulation is administered transurethrally, topically, or transdermally.